stents

Disección coronaria en mujeres: poco frecuente y de difícil manejo

Revascularization in Spontaneous Coronary Artery Dissection Causing ST-Segment Elevation Myocardial Infarction

Spontaneous coronary artery dissection is an increasing cause of acute myocardial infarction, particularly in younger women. These infarctions are frequently treated conservatively given the risks entailed by revascularization, due to the possibility of causing an antegrade or retrograde expansion of the dissection. The uncertainty around treatment for these patients gave way to this study (recently<a href="https://solaci.org/en/2019/09/24/revascularization-in-spontaneous-coronary-artery-dissection-causing-st-segment-elevation-myocardial-infarction/" title="Read more" >...</a>

DKCRUSH-V: El tronco de la coronaria izquierda no es una bifurcación más

DK CRUSH Is Still The Best Option

Courtesy of Dr. Carlos Fava. When it comes to severe unprotected left main distal bifurcation lesions, surgery continues to be the preferred treatment option. However, due to the growing number of patients that cannot receive surgery, left main PCI has significantly advanced, and though the strategy in this scenario remains controversial, double kissing crush stenting<a href="https://solaci.org/en/2019/09/19/dk-crush-is-still-the-best-option/" title="Read more" >...</a>

Struts finos, muy finos y ultrafinos con polímero permanente o degradable ¿Cuál es la mejor combinación?

Thin, Very Thin, and Ultrathin Struts, with Permanent or Biodegradable Polymer&#8230; Which Is the Best Combination?

Results from the BIO-RESORT trial at three years, soon to be published in JACC Intv., show that, despite significant differences among stents as regards strut thickness and capability to reabsorb the polymer, there are no apparent safety or efficacy differences among devices. The aim of this study was to determine the three-year safety and efficacy<a href="https://solaci.org/en/2019/09/18/thin-very-thin-and-ultrathin-struts-with-permanent-or-biodegradable-polymer-which-is-the-best-combination/" title="Read more" >...</a>

Infarto agudo de miocardio y lesiones de múltiples niveles

STEMI in Coronary Dissections. When Should We Do It and What Are Its Outcomes?

Courtesy of Dr. Carlos Fava. Generally, coronary artery dissection (SCAD) is not very frequent in young women and presents better evolution with medical treatment. However, it is occasionally associated with ST segment elevation. In this scenario, PCI with stent implantation is quite challenging. The study looked at 4298 STEMI patients; 53 presented SCAD (1.23%). STEMI-SCAD<a href="https://solaci.org/en/2019/09/17/stemi-in-coronary-dissections-when-should-we-do-it-and-what-are-its-outcomes/" title="Read more" >...</a>

mas-leido-agosto

The Most Read Articles of August in solaci website

1-FDA Expands TAVR Indication to Low-Risk Patients Both the self-expandable valve Evolut R and its direct competitor, balloon-expandable valve Sapien 3, received the authorization to be indicated for low-risk patients in a long-awaited announcement made on August 16th, 2019. Read also HERE 2-Mechanisms of Post PCI Persistent Angina Angina persistence or recurrence after PCI can<a href="https://solaci.org/en/2019/09/16/the-most-read-articles-of-august-in-solaci-website/" title="Read more" >...</a>

synergy vs XIENCE

Theoretical Advantages Translated into Worst Clinical Outcomes: Synergy vs. Xience

New data from a real-world registry soon to be published in J Am Coll Cardiol Intv suggest that Synergy (a thin-strut everolimus-eluting stent with a biodegradable polymer) is associated with a higher risk of acute stent thrombosis when compared with classic Xience (a thicker-strut everolimus-eluting stent with a durable polymer). At 12 months, there was<a href="https://solaci.org/en/2019/09/10/theoretical-advantages-translated-into-worst-clinical-outcomes-synergy-vs-xience/" title="Read more" >...</a>

ESC 2019 | SYNTAXES: Ten-Year Outcomes!

The SYNTAXES (SYNTAX Extended Survival) was presented at ESC 2019 with somewhat unexpected results in favor of PCI. This is why the SYNTAX continues to be one of the best studies interventional cardiologists can rely on. The original SYNTAX tested mortality (primary end point) with PCI vs. CABG in patients with multivessel and/or left main<a href="https://solaci.org/en/2019/09/06/esc-2019-syntaxes-ten-year-outcomes/" title="Read more" >...</a>

Lo más leído de Julio en solaci.org

The Most Read Articles of July in solaci website

1-Though Systolic BP Seems More Important, Diastolic BP Should Not Be Disregarded Systolic hypertension is more often associated to cardiovascular events. However, diastolic blood pressure should not be disregarded, since it can also predict even worse outcomes. Read more HERE 2-After Much Toing and Froing, Gastrointestinal Protection Is Back to the Forefront Several clinical guidelines<a href="https://solaci.org/en/2019/08/30/the-most-read-articles-of-july-in-solaci-website/" title="Read more" >...</a>

Sinus Aspiration against Contrast Induced Kidney Injury

Mechanisms of Post PCI Persistent Angina

Angina persistence or recurrence after PCI can affect between 20 to 40% of patients in the short and mid-term. This might be true despite PCI optimization using FFR, intravascular ultrasound and the latest generation stents. This problem is associated with high healthcare cost, which can double in patients with recurrent or persistent angina compared against<a href="https://solaci.org/en/2019/08/22/mechanisms-of-post-pci-persistent-angina/" title="Read more" >...</a>

Efecto a largo plazo de los balones liberadores con bajas dosis de paclitaxel

New FDA Updates on Paclitaxel Device Outcomes

A new FDA letter confirms late mortality signal with paclitaxel eluting stents and paclitaxel coated balloons in peripheral territory. Even though this recently published letter confirms data, there are no new recommendations on the use of these devices. After careful consideration of their own analyzis outcomes and a 2-day discussion of an advisory panel especially<a href="https://solaci.org/en/2019/08/12/new-fda-updates-on-paclitaxel-device-outcomes/" title="Read more" >...</a>

Top